A UK-based KOL discusses the prostate cancer treatment pathway across multiple settings, as well as the use of Cambridge Prognostic Group scoring, PSMA-PET access and the positioning of androgen receptor pathway inhibitors, doublet and triplet regimens. NICE reimbursement decisions and their effect on NHS practice were a recurring theme, alongside biomarker testing rates, choice of androgen deprivation formulation and treatment attrition in later lines.

This interview was conducted on March 13, 2026. 

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.